



CANCER CARE AT THE CROSSROADS

 CA, October 18, 2024

A One-Day International Summit on Innovation, Clinical Benefit and Cost

Meet the Sponsors

EVERNORTHSM

Genentech
A Member of the Roche Group



UCSF Health



9:00 am to 9:15 am

Welcome and Opening Remarks

Setting the Stage for the Day



DAN'L LEWIN

President and Chief Executive Officer
Computer History Museum



THOMAS J. LYNCH, JR., MD

President and Director
Fred Hutchinson Cancer Center



MIKE MEYER

President and Founder
Meyer Consulting

Opening Remarks

9:15 am to 10:15 am

Roundtable 1

Cancer Care Through the Lens of Health Plans, Academic Centers, Employers, Pharma and Provider Groups



Moderator

THOMAS J. LYNCH, JR., MD

President and Director
Fred Hutchinson Cancer Center



Panelist

CHARLES BACCHI

President & CEO
California Association of Health Plans



Panelist

SURESH GUNASEKARAN, MBA

President and Chief Executive Officer
UCSF Health



Panelist

CLIFFORD A. HUDIS, MD, FACP, FASCO

Chief Executive Officer
American Society of Clinical Oncology (ASCO)



Panelist

ASHLEY MAGARGEE, MBA

Chief Executive Officer
Genentech

Roundtable 1

10:15 am to 10:30 am

10:30 am to 11:30 am

Roundtable 2
The Future of Cancer Science



Moderator
WILLIAM DAHUT, MD
Chief Scientific Officer
American Cancer Society



Panelist
DAVID CHAMBERS, DPhil
Deputy Director for
Implementation Science
*Division of Cancer Control and
Population Sciences, NCI*



Panelist
PRITI HEGDE, PhD
Senior Vice President and
Global Head of Research
Kite Pharma



Panelist
**TONY MOK, BMSc, MD, FRCP(C),
FRCP, FHKCP, FHKAM, FASCO**
Chairman of Department of Clinical
Oncology, *The Chinese University of
Hong Kong*



Panelist
DAVID M. REESE, MD
Executive Vice President, Chief
Technology Officer
Amgen

Roundtable 2

11:30 am to 12:30 pm

Roundtable 3
Improving Patient Outcomes Through Innovations in Care Delivery



Moderator
**TAEJOON AHN, MD, MPH,
CPE**
President and CEO
John Muir Medical Group



Panelist
**CHRISTOPHER BIGGS, MD,
PhD**
Chief Managing Officer
Arizona Center for Cancer Care



Panelist
**MARGARET B. ROW, MD, MBA,
FACP**
Professor *University of Texas,
MD Anderson Cancer Center*



Panelist
HOPE S. RUGO, MD, FASCO
Prof. of Medicine and Winterhof Family
Prof. of Breast Oncology
Dir., Breast Oncology and Clinical Trials
Education, Medical Dir., Cancer Infusion
Svcs., Div. of Hematology/Oncology,
*UCSF Helen Diller Family
Comprehensive Cancer Center*



Panelist
CORNELIA ULRICH, PhD, MS
Chief Scientific Officer and
Executive Director, Comprehensive
Cancer Center
Huntsman Cancer Institute
Jon M. and Karen Huntsman
Presidential Professor in Cancer
Research

Round Table 3

1:30 pm to 2:30 pm

Roundtable 4

The Challenges Facing Health Plans, Pharma, Providers and Government in Financing Expensive Innovative Cancer Treatments



Moderator
GLEN STETTIN, MD
Chief Innovation Officer
Evernorth



Panelist
TERRY GILLILAND, MD
President and Chief Executive Officer
Geisinger



Panelist
EDWARD KIM, MD
Vice Physician-in-Chief, *City of Hope National Medical Center*
and Physician-in-Chief, *City of Hope Orange County*



Panelist
KETAN PARANJAPPE, MBA, PhD
Chief Operating Officer and SVP
Engineering of Enterprise Imaging
Optum



Panelist
SUNIL VERMA, MD, MSc, FRCPC
Senior Vice President, Global Head,
Oncology Franchise Organization
AstraZeneca

Roundtable 4

2:30 pm to 2:50 pm

Break

2:50 pm to 3:50 pm

Roundtable 5

AI and Analytics in Oncology



Moderator
ANDREW BINDMAN, MD
EVP and Chief Medical Officer
Kaiser Permanente



Panelist
CAROLINE CHUNG, MD
Vice President and Chief Data
Officer and Director of Data Science
Development and Implementation
of the Institute for Data Science in
Oncology
MD Anderson Cancer Center



Panelist
JAMES HAMRICK, MD
Vice President of Clinical Oncology
Flatiron Health



Panelist
THOMAS OSBORNE, MD
Chief Medical Officer
Microsoft: Federal Civilian



Panelist
SYLVIA K. PLEVITIS, PhD
Chair, Department of Biomedical
Data Science
*Stanford University School of
Medicine*

Roundtable 5

Panelist Bios



TAEJOON AHN, MD, MPH, CPE

President and CEO
John Muir Medical Group

Taejoon Ahn became the president of John Muir Medical Group (JMMG) in January of 2014. He leads a medical group of over 350 clinicians, mostly in primary care. JMMG is the exclusive contracted provider of primary care services for John Muir Health, partnering closely for close to 30 years. Previously, Dr. Ahn served as vice president and medical director of urgent care services for JMMG. He also worked as faculty for the University of California, San Francisco's National HIV/AIDS Clinicians' Consultation Center and is currently an Assistant Clinical Professor of Family & Community Medicine for UCSF.

Dr. Ahn currently serves on the boards of John Muir Health and Canopy Health. Canopy Health is a joint venture between multiple provider groups to offer a large network in the San Francisco Bay Region.

Dr. Ahn has served in various capacities for the California Academy of Family Physicians. Current service includes Audit/Compliance Committee and the Medical Practice Affairs Committee. He has also served on CAFP's Board of Directors, Legislative Affairs Committee as Chair and for the California Medical Association's specialty delegation and council on legislation.

Dr. Ahn received his medical degree from the University of California San Francisco, where he also completed a residency in Family & Community Medicine. He received his Masters in Public Health with an emphasis in Epidemiology from UC Berkeley. He is an alumnus of the California Healthcare Foundation's Leadership Fellowship and is a certified physician executive with the American Association for Physician Leadership (formerly the American College of Physician Executives).



CHARLES BACCHI

President & CEO
California Association of Health Plans

Charles Bacchi is the President & CEO for the California Association of Health Plans (CAHP) representing 41 health plans providing coverage to over 28 million Californians. For the last 18 years Mr. Bacchi served in leadership positions at CAHP, as Executive Vice President and Vice President of Legislative Affairs, leading the Association's advocacy before the California Legislature, the California Health Benefit Exchange, Department of Health Care Services, and the Department of Managed Health Care on behalf of CAHP's health plan members.

A veteran of California's political community, Mr. Bacchi has nearly 30 years of experience in California's legislative, advocacy, and trade association arenas. Under the Affordable Care Act, health plans play a critical role in offering millions of Californians access to health care. As state policymakers crafted California's approach to ACA implementation, Bacchi played a prominent role as the health plan voice on a range of issues, including translation of the ACA into state law, the start-up of Covered California, and the expansion of the state's Medicaid program, Medi-Cal.



CHRISTOPHER BIGGS, MD, PhD

Chief Managing Officer
Arizona Center for Cancer Care

Dr. Christopher Biggs specializes in radiation oncology and is an expert in radiosurgery and gynecological oncology.

Dr. Biggs co-founded Arizona Center for Cancer Care in 2008 with Drs. Daniel Reed and Terry Lee. He attended the University of Arizona, where he received his Bachelor of Science degree in Molecular and Cellular biology. His interest in cancer research took him to the University of Southern California, under the Borchard Cancer Research Fellowship. There, he performed research on the molecular genetics of cancer at the Norris Cancer Center and at LA Children's Hospital. After completing his Doctor of Philosophy degree, he moved to Stanford University, where he earned his medical degree, and developed an interest in radiation oncology. Dr. Biggs completed his residency in radiation oncology at the University of California, San Francisco, where he eventually served as chief resident.

For five years, Dr. Biggs performed radiosurgery at Barrow Neurological Institute and served as director of the Baptist Oncology Center.

Dr. Biggs is certified by the American Board of Radiology and is a Diplomate of the American Society of Therapeutic Radiation Oncology. He is a member of the American Association for Cancer Research, Radiology Society of North America, American Society of Therapeutic Radiation Oncology and the American Association of Advancement of Science.

Dr. Biggs is a multi-year "Top Doc" honoree by Phoenix Magazine.



ANDREW BINDMAN, MD

EVP, Chief Medical Officer,
National Health Plan and Hospitals Quality
Kaiser Foundation Health Plan and Hospitals

Andrew Bindman, MD, is executive vice president and chief medical officer for Kaiser Permanente. He is responsible for driving superior quality and equitable health outcomes through the integration of quality innovation, care delivery, data analytics, and research in collaboration with the Permanente Medical Groups. He is also Kaiser Permanente's executive sponsor for the Kaiser Permanente Bernard J. Tyson School of Medicine.

Prior to joining Kaiser Permanente, Dr. Bindman spent more than 30 years on the faculty at the University of California, San Francisco where he practiced and taught internal medicine while conducting research on health access and outcomes that resulted in more than 200 published scientific articles. He also served as the Director of the Agency for Healthcare Research and Quality in 2016-2017.

Dr. Bindman is a graduate of Harvard College and the Mount Sinai School of Medicine. A board-certified general internist, he completed his residency in internal medicine at UCSF and was a Robert Wood Johnson Foundation Clinical Scholar at Stanford University. He is an elected member of the National Academy of Medicine and the Association of American Physicians.



DAVID CHAMBERS, DPhil

Deputy Director for Implementation Science
Division of Cancer Control and Population Sciences, NCI

Dr. David Chambers is Deputy Director for Implementation Science in the Office of the Director in the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI). Dr. Chambers manages a team focusing on efforts to build and advance the field of Implementation Science (IS) through funding opportunities, training programs, research activities, dissemination platforms, and enhancement of partnerships and networks to integrate research, practice and policy.

From 2008 through the fall of 2014, Dr. Chambers served as Chief of the Services Research and Clinical Epidemiology Branch (SRCEB) of the Division of Services and Intervention Research at the National Institute of Mental Health (NIMH). He arrived at NIMH in 2001, brought to the Institute to run the Dissemination and Implementation Research Program within SRCEB, developing a portfolio of grants to study the integration of scientific findings and effective clinical practices in mental health within real-world service settings. From 2006 to the fall of 2014, Dr. Chambers also served as Associate Director for Dissemination and Implementation Research, leading NIH initiatives around the coordination of dissemination and implementation research in health, including a set of research announcements across multiple NIH Institutes and Centers, annual scientific conferences, and a summer training institute.

Prior to his arrival at NIH, Dr. Chambers worked as a member of a research team at Oxford University, where he studied national efforts to implement evidence-based practice within healthcare systems. He publishes on strategic research directions in implementation science and serves as a plenary speaker at numerous scientific conferences. He received his A.B. degree (with Honors) in Economics from Brown University in 1997, and an M.Sc. and D.Phil degree in Management Studies (Organisational Behaviour) in 1998 and 2001, respectively, from Oxford University (UK).



CAROLINE CHUNG, MD

Vice President and Chief Data Officer and
Director of Data Science Development and Implementation of the
Institute for Data Science in Oncology
MD Anderson Cancer Center

Dr. Chung is Vice President and Chief Data Officer and Director of Data Science Development and Implementation of the Institute for Data Science in Oncology at MD Anderson Cancer Center. She is a clinician-scientist, associate professor in Radiation Oncology and Diagnostic Imaging with a clinical practice focused on CNS malignancies and a computational imaging lab focused on quantitative imaging and modeling to detect and characterize tumors and toxicities of treatment to enable personalized cancer treatment. Motivated by challenges observed in her own clinical and research pursuits, Dr. Chung has developed and leads institutional efforts to enable quantitative measurements for clinically impactful utilization and interpretation of data through a collaborative team science approach, including the Tumor Measurement Initiative (TMI) at MD Anderson. Internationally, Dr. Chung leads several multidisciplinary efforts to improve the generation and utilization of high quality, quantitative data to drive research and impact clinical practice, including her role as Vice Chair of the Radiological Society of North America (RSNA) Quantitative Imaging Biomarker Alliance (QIBA), Co-Chair of the Quantitative Imaging for Assessment of Response in Oncology Committee of the International Commission on Radiation Units and Measurements (ICRU) and National Academies of Sciences, Engineering, and Medicine (NASEM)-appointed committee addressing Foundational Research Gaps and Future Directions for Digital Twins. Beyond her clinical, research and administrative roles, Dr. Chung enjoys serving as an active educator and mentor with a passion to support the growth of diversity, equity and inclusion in STEM, including her role as Chair of Women in Cancer <http://www.womenincancer.org/>, a non-for-profit organization that is committed to advancing cancer care by encouraging the growth, leadership and connectivity of current and future oncologists, trainees and medical researchers.

Panelist Bios



WILLIAM DAHUT, MD

Chief Scientific Officer
American Cancer Society

Dr. Dahut, is CSO of the American Cancer Society, where he oversees the strategic direction of intramural and extramural research for the largest nonprofit funder of cancer research. Dr. Dahut manages all pieces of ACS' Discovery Pillar, including surveillance and health equity science, population science, cancer screening guidelines, and extramural discovery science. He serves as the scientific voice of the organization, advises key discovery positions, and manages more than \$400 million in research funding. Dr. Dahut guides efforts to enhance and focus the American Cancer Society's research program, concentrating priorities where they will be most effective and working with key partners and supporters to further progress.

Dr. Dahut is leading the Discovery Pillar's contribution to the organization's mission to improve the lives of people with cancer and their families, ensuring everyone has an opportunity to prevent, detect, treat, and survive cancer. That includes: the launch of a new ACS Center for Diversity in Research Training; a new cohort focused on Black women that will launch in pilot markets in 2023; and a new IMPACT initiative focusing on reducing disparities in prostate cancer mortality in Black men.

Dr. Dahut leads a team of researchers seeking to "end cancer as we know it, for everyone." His team is working to fund cancer research, in areas often overlooked by other organizations. They are increasing their focus on screening, early detection, prevention, and detection of cancer recurrence, and looking into research on health care implementation; emphasizing the scientific importance of diversity, equity, and inclusion in all aspects of Discovery-funded research; and providing opportunities to accelerate bench-to-bedside work.

An internationally recognized physician-investigator, Dr. Dahut held roles at the NCI before joining ACS as scientific director for clinical research at the NCI's Center for Cancer Research; head of the prostate cancer clinical research section, and NCI clinical director. Dr. Dahut's career has been focused on helping cancer patients. As a champion of clinical science, he has pioneered treatment regimens in prostate cancer and is an expert in clinical trials and immunotherapy.

He received his MD from Georgetown University and was clinically trained in internal medicine at the National Naval Medical Center, followed by training in hematology and medical oncology at the Bethesda Naval Hospital and the Medicine Branch of the NCI. Dr. Dahut sits on numerous boards and committees, has won distinguished honors and awards, and is a published author, with nearly 250 pieces in peer-reviewed journals. He is chair-elect of the Department of Defense Prostate Cancer Research Program Integration Panel, has spoken to audiences across the country and around the world, and trained dozens of medical oncology fellows. He is also professor of medicine at Uniformed Services University of the Health Sciences in Bethesda, Maryland, and sees patients in the prostate cancer clinic at Walter Reed National Medical Military Center.



SURESH GUNASEKARAN, MBA

President and Chief Executive Officer
UCSF Health

Suresh Gunasekaran, MBA is president and chief executive officer (CEO) of UCSF Health, an internationally recognized health system that includes UCSF Benioff Children's Hospitals, Langley Porter Psychiatric Hospital and Clinics, UCSF Benioff Children's Physicians and the UCSF Faculty Practice. UCSF Health includes approximately 18,000 staff and physicians, maintains 1290 beds, admits 41,000 patients and has over 2.5 million outpatient visits yearly, and has annual revenue of more than \$5 billion.

Gunasekaran also oversees UCSF Health's expanding network of affiliated health care organizations throughout Northern California. U.S. News & World Report consistently ranks UCSF Medical Center among the country's top 10 hospitals and UCSF Benioff Children's Hospitals among the nation's best pediatric medical centers.

Gunasekaran leads the execution of UCSF Health's vision and the institution's next phase of growth, revitalization and innovation, including in the area of technology. He partners with UCSF's research and education enterprises and upholds the health system's PRIDE (Professionalism, Respect, Integrity, Diversity and Excellence) values, and commitment to advancing anti-racism and social justice.

Gunasekaran has more than 20 years of experience in health care administration and information technology, with a focus on quality and safety, patient service, collaboration and operational excellence. He most recently was CEO of University of Iowa Hospitals & Clinics and associate vice president for University of Iowa Health Care. He led the clinical enterprise of Iowa's only comprehensive academic medical center, a more than \$2 billion operation with 11,000 employees. He previously served as chief information officer and then chief operations officer for the health system of University of Texas Southwestern Medical Center. He began his career in health care as an administrative director in outpatient clinical operations at Children's Hospital at Vanderbilt. He also worked as an analyst for both Gartner and IBM/Healthlink.

Gunasekaran earned a master of business administration degree, graduating with honors, from Southern Methodist University.



TERRY GILLILAND, MD

President and Chief Executive Officer
Geisinger

Dr. Terry Gilliland was named Geisinger's new president and chief executive officer in 2024. He has extensive healthcare experience and has held senior executive roles spanning healthcare delivery and payer organizations. Most recently, Dr. Gilliland served as chief medical officer and chief science officer at Cogitativo, a healthcare-focused artificial intelligence and machine learning company. Prior to that, he served as executive vice president of Healthcare Quality and Affordability at Blue Shield of California and senior vice president and chief medical officer of Sentara Healthcare. Earlier in his career, Dr. Gilliland held various leadership roles at the Mid-Atlantic Permanente Medical Group and the Colorado Permanente Medical Group within Kaiser Permanente, in addition to being a practicing general surgeon.

Dr. Gilliland received his Bachelor of Science in Biology from Stanford University, his Doctor of Medicine from the University of California, Los Angeles, and his Master of Science in Management from the Stanford Graduate School of Business.



JAMES HAMRICK, MD

Vice President of Clinical Oncology
Flatiron Health

Dr. Hamrick leads a team of physicians, nurses, and informatics specialists who inform the development and applications of the Flatiron HC products and services relied upon by front-line clinicians in hundreds of cancer clinics across the United States.

Prior to joining Flatiron Health, Dr. Hamrick served as chief of medical oncology and hematology at Kaiser Permanente Georgia. He is on the board of the Georgia Center for Oncology Research and Education and previously served on the Kaiser Permanente National Inter-Regional Cancer Leadership Council and the KP National Cancer Chiefs Council.

Dr. Hamrick received his MD and an MPH in epidemiology from the University of North Carolina at Chapel Hill. He completed his residency and hematology/oncology fellowship at the University of California San Francisco. He is board-certified in internal medicine, medical oncology, and hematology.



PRITI HEGDE, PhD

Senior Vice President & Global Head of Research
Kite Pharma a Gilead Company

Priti Hegde is SVP and global head of Research at Kite Pharma a Gilead company, with a focus on developing novel engineered cellular therapies for diseases including Cancer and inflammatory diseases. From 2019 to 2023, Priti was Chief Scientific Officer at Foundation Medicine, a Roche company, where she led research and development of molecular diagnostic tools for Cancer. Prior to that, Priti spent over a decade at Genentech where she led the Cancer Immunotherapy translational program.

Prior to Genentech, she led the transcriptomics organization at GSK. Priti received her post-doctoral training in Human Genomics at The Institute for Genomics Research and her PhD in Biochemical Pharmacology from SUNY at Buffalo. Priti serves as a member of board of directors at Adaptimmune and has been on the scientific advisory board of Bolt Therapeutics.



CLIFFORD A. HUDIS, MD, FACP, FASCO

CEO,
American Society of Clinical Oncology (ASCO)

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice Chair of its Conquer Cancer Foundation and Chair of ASCO's CancerLinQ. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society's 50th anniversary year (2013-14). Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board's strategic goals through education, research, and support for the delivery of the highest quality of care by the Society's nearly 50,000 members.

Panelist Bios



EDWARD S. KIM, MD

Vice Physician-in-Chief, *City of Hope National Medical Center* and Physician-in-Chief and Senior Vice President, *City of Hope Orange County*

Edward S. Kim, MD, MBA, FACP, FASCO, is physician-in-chief and senior vice president, City of Hope Orange County, Construction Industries Alliance City of Hope Orange County Physician-in-Chief Chair, Vice Physician-in-Chief and Professor, City of Hope, and System Director, Clinical Trials. Dr. Kim is among the country's foremost experts in molecular prognostication - which advances cancer detection and personalized therapies - for lung, head, and neck cancers. He has served as a principal/co-principal investigator on numerous studies and protocols and authored/co-authored more than 250 published articles, book chapters, and reviews in top-tier journals such as *The Lancet*, *The Lancet Oncology*, *Journal of Clinical Oncology*, *Cancer Discovery*, *Cancer*, *Nature Medicine*, and *Cancer Prevention Research*. Only of only 15 physicians from around the world honored as a 2024 Giant in Cancer Care, Dr. Kim has also been repeatedly recognized among cancer care's leading advocates for diversity, equity, and inclusion. A respected clinician, researcher, and physician executive, he is a trailblazer who is eliminating practices that exclude minority populations from clinical trials and result in serious gaps in care and research.



DAN'L LEWIN

President and Chief Executive Officer
Computer History Museum

Dan'l Lewin is the President and Chief Executive Officer of the Computer History Museum (CHM), a nonprofit organization with a four-decade history exploring the world's computing past, digital present, and future impact of technology on humanity. Lewin directs the strategic planning, fundraising, and ongoing operations of CHM. Prior to CHM, Lewin led Microsoft's work in applying technology for public good during a 17-year tenure. He collaborated cross-company and with external partners to focus on scalable impact, with a portfolio that includes establishing the company's global startup and venture capital engagement model, its campaign and civic tech engagement efforts, affordable internet access initiatives, environmental sustainability work, and partnerships with leading research universities. Prior to Microsoft Lewin accrued 30-plus years of leadership experience in Silicon Valley with companies that include NeXT, Apple, Go Corporation, and Sony. Among others, Lewin has served on the boards of the Silicon Valley Community Foundation, UI Labs, and Advanced Energy Economy, and currently serves as a Board Director at StartX, xMentium, and Persistent Systems. He is also on the Advisory Council for the Department of Politics at Princeton University. Lewin holds an AB in Politics from Princeton University.



THOMAS J. LYNCH, JR., MD

President and Director
Fred Hutchinson Cancer Center

Dr. Thomas J. Lynch Jr. is a world-renowned scientist, highly respected oncologist and successful NCI-designated comprehensive cancer center leader. As the President and Director of Fred Hutchinson Cancer Center and holder of the Raisbeck endowed chair, Dr. Lynch brings more than three decades of experience at highly regarded U.S. cancer centers. He has expertise in solid tumor research, precision medicine and discoveries in fundamental biology. Before joining Fred Hutch, Dr. Lynch held leadership roles as CSO at Bristol-Myers Squibb, CEO of Massachusetts General Physicians Organization, director of Yale Cancer Center, physician-in-chief at Yale's Smilow Cancer Hospital, as well as chief of hematology-oncology at Massachusetts General Hospital and professor of medicine at Harvard Medical School. Dr. Lynch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.



ASHLEY MAGARGEE

Chief Executive Officer
Genentech

In January 2024, Ashley Magargee assumed the role of chief executive officer of Genentech, a member of the Roche Group, and joined Genentech's Board of Directors. As CEO, Ashley's primary responsibilities are to provide strategic leadership for Genentech, cultivate a vibrant culture that inspires employees to be their best, and bring life-changing medicines to patients.

Ashley was previously head of the Commercial Portfolio Organization, responsible for the overall performance of Genentech's approved medicines in the United States. During her tenure in this role, she successfully launched numerous groundbreaking medicines for people with serious conditions and also expanded the company's presence in several therapeutic areas.

Throughout her nearly two-decade career at Genentech and Roche, Ashley has led global cross-functional teams to develop and commercialize innovative medicines worldwide. She has also been instrumental in shaping the company's digital customer engagement strategy and has held leadership positions in access, marketing and sales leadership for therapeutic areas such as hematology, lung cancer and transplant. Additionally, Ashley served as the general manager for Roche's commercial operations in Singapore and Brunei.

Early in her career, Ashley worked on Capitol Hill, focusing on health policy under Senator Tom Daschle, the Democratic Leader of the U.S. Senate. She also served as assistant principal at the St. Mark the Evangelist School in Harlem, where she witnessed firsthand the profound impact of sickle cell disease on her students. These experiences in public service laid a strong foundation for Ashley's subsequent transition into the biopharmaceutical industry. Here, she has sought to leverage the industry's innovation, reach and resources to bring about transformative medicines and healthcare solutions for patients in critical need.

Ashley is a firm believer that encouraging a diversity of backgrounds, thoughts and experiences is critical to fueling scientific and customer innovation. She is dedicated to cultivating an environment where all employees are included and empowered; advancing Genentech's commitment to inclusive research and health equity; and transforming society through sustainable solutions that address inequities in healthcare, advance STEM education and support Genentech's local communities.

Ashley serves on the Board of Directors for the Pharmaceutical Research and Manufacturers of America. She graduated from Princeton University and earned her MBA from Harvard University. Ashley resides in the San Francisco Bay Area with her husband and three sons.



MIKE MEYER

President and Founder
Meyer Consulting

Mike Meyer is an entrepreneur, author, health care expert, and founder and host of the CCX Cancer Care at the Crossroads Summit. He is the President of Meyer Consulting. Early in the pandemic, he coauthored an op-ed in the Wall Street Journal titled Medical Lockdown will Cause a Disease Surge, which proved remarkably accurate. He is known for his work with leading health systems, academic medical centers and health care companies. Over the years, he has built or helped grow multiple health care companies.

Meyer founded Meyer Consulting in 2007 to offer healthcare organizations a consulting firm that has a unique business model encompassing executive search, strategic consulting, and human capital consulting. Meyer's current and former clients include Memorial Sloan Kettering Cancer Center, Mayo Clinic, Blue Cross Blue Shield Association, Horizon Blue Cross Blue Shield NJ, Pfizer, MD Anderson Cancer Center, Summit Medical Group, California Association of Health Plans, WIN Consortium for Personalized Cancer Medicine and numerous other academic centers, large providers, physician groups and other not-for-profit health care organizations.

Meyer's early career was as vice president in charge of the New York office of Amherst Associates, which went public in 1981. He subsequently became a senior partner with Witt Kieffer. Meyer founded Cancer Care at the Crossroads (CCX) Summit in 2016. This one-of-a-kind event brings together senior health care executives from the US and international. In 2019 Meyer Consulting's executive search practice was acquired by Westwood & Wilshire, a premier firm in life sciences and technology.

Meyer was a board member of Summit Select, part of Summit Medical Group which merged with CityMD, creating one of the largest private physician groups in the U.S., with support from Warburg Pincus. He cofounded the Institute for Mental Health Research www.imhr.org and was a board member of the Human Health and Research Foundation <http://hherf.org>. He has been widely quoted on healthcare, oncology, mental health and retiree topics in healthcare and business publications. He is the author of Catastrophic Illness and Catastrophic Health Insurance published by the Heritage Foundation, and coauthor of Destination Southwest, a Guide to Retiring and Wintering in Arizona.



TONY S.K. MOK, BMSc, MD, FRCP(C), FRCP, FHKCP, FHKAM, FASCO

Chairman of Department of Clinical Oncology
The Chinese University of Hong Kong

Professor Tony S.K. Mok is the Li Shu Fan Medical Foundation Endowed Professor and Chairman of Department of Clinical Oncology at The Chinese University of Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has led and co-led multiple international phase III studies. These projects address various aspects on management of advanced lung cancer, and basically have defined the current practice.

Professor Mok has contributed to over 315 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet, Nature Medicine and Journal of Clinical Oncology, and published multiple editorials and textbooks. His work was recognized by numerous awards, his recent received awards: ESMO Lifetime Achievement Award in 2018, The 6th Kobayashi Foundation Award, Giant of Cancer Care, Bronze Bauhinia Star (BBS) by the Government of Hong Kong Special Administrative Region in 2022 and The Sixth Fok Ying-Tung Prize The World Outstanding Chinese Doctor Award in 2023. His article in the New England Journal of Medicine has been selected as one of the most "Notable Articles in 2017." He is one of the "Highly Cited Researchers" by Clarivate Analytics for five consecutive years from 2018 to 2023.

Panelist Bios



THOMAS OSBORNE, MD

Chief Medical Officer
Microsoft: Federal Civilian

Thomas Osborne MD is Chief Medical Officer for Microsoft, Federal Civilian. Prior to joining Microsoft, he held various executive leadership roles at VA and industry. Throughout his career, Dr. Osborne has collaborated broadly and leveraged the latest technologies to positively transform healthcare, such as artificial intelligence, cloud computing, 5G, sensor technology, wearables, robotics, augmented reality, and virtual reality. Dr. Osborne has received numerous national awards for his translational work that have been published in leading medical journals and textbooks on a wide range of topics such as cancer, infectious disease, neurologic disease, surgery, pain, climate, falls, elder care, determinants of health, telehealth, diagnostics, predictive analytics, health risk, efficiencies, advanced health technology, big data analytics, and the future of health care. Dr. Osborne received his medical degree from Dartmouth Medical School and completed his clinical residency and fellowship at Harvard hospitals.



KETAN PARANJAPE, MBA, PhD

Chief Operating Officer and
SVP of Engineering of Enterprise Imaging
Optum

Ketan is both the Chief Operating Officer and SVP of Engineering of Enterprise Imaging at Optum. In his role he is responsible for global strategic and day to day operations management for global production & logistics, implementation services, support, customer success, and revenue operations. His team is also building their next generation cloud-based Enterprise Imaging platform to support SaaS transformation to solve the core problems of Medical Imaging: cost, productivity, and information overload. Prior to this he was the Vice President of Commercial Business Operations, Business Intelligence and Analytics at Roche and was the VP of Roche Information Solutions business focused on harnessing the power of data, diagnostics, and other critical information to support better clinical decisions. Before that Ketan was the Managing Director at Health2047, a startup funded by the American Medical Association developing and commercializing solutions for data liquidity, chronic care, productivity, security, and payments. Along with being the former VP and GM at Intel Corporation, he has been the global head of product and engineering.

He is currently on the roster of experts on Digital Health at the World Health Organization. He has been a member of the US Health IT Standards Committee Precision Medicine Task Force, AAAS-FBI-UNICRI Project on Life Sciences and National and Transnational Security, International Telecommunication Union's Global Cybersecurity Working Group and WHO's Experts Working Group on eHealth. Ketan holds a Ph.D. in Artificial Intelligence from the Vrije Universiteit Amsterdam, MS degrees in Electrical Engineering and Computer Sciences from the Univ. of Wisconsin and an MBA from the Univ. of Oregon.



SYLVIA K. PLEVritis, PhD

Chair, Department of Biomedical Data Science
Stanford University School of Medicine

Sylvia K. Plevritis, PhD, is Professor of Biomedical Data Science and of Radiology, and Chair of the Department of Biomedical Data Science. She is a thought leader on the expanded use of artificial intelligence and machine learning (AI/ML) in academic research and education. An electrical engineer by training, Plevritis' cancer systems biology research program has been deciphering tumor heterogeneity by pioneering novel AI/ML analytics on multimodal biomedical data sets from human tumors. Plevritis is also a contributor to data-driven computer simulation models that guide national cancer screening guidelines for early detection of breast and lung cancers. Plevritis serves on the NCI Board of Scientific Advisors and is a fellow of the American Institute for Medical and Biological Engineering and Distinguished Investigator in the Academy of Radiology Research.



DAVID M. REESE, MD

Executive Vice President, Chief Technology Officer
Amgen

David M. Reese, M.D., is executive vice president and Chief Technology Officer (CTO). In this role, Reese oversees Digital and Technology Innovation, the Office of the Chief Medical Officer, and the development and deployment of artificial intelligence across the enterprise.

Reese joined Amgen in 2005 and previously served in various leadership roles within the Research and Development organization. This includes most recently functioning as executive vice president of Research and Development, where he oversaw Amgen's worldwide research efforts and the advancement of Amgen's pipeline in all therapeutic areas.

Prior to joining Amgen, Reese was director of Clinical Research for the Breast Cancer International Research Group (BCIRG) and a co-founder, president and Chief Medical Officer of Translational Oncology Research International (TORI), a not-for-profit academic clinical research organization. Reese is a graduate of Harvard College and the University of Cincinnati College of Medicine. He completed training in Internal Medicine and Hematology/Oncology at the University of California, Los Angeles (UCLA) School of Medicine and subsequently served on the faculty at UCLA and the University of California, San Francisco.



MARGARET B. ROW, MD, MBA, FACP

Professor
University of Texas, M.D. Anderson Cancer Center

Dr. Margaret B. "Maggie" Row is a proven clinician with expertise across the entire continuum of care of oncology patients. Row also has extensive experience in clinical operations spanning the entire healthcare spectrum including network development, physician recruitment, leadership development, oncology program development, clinical quality, and value.

Dr. Row's clinical expertise is in internal medicine, urgent care of the oncology patient, cancer risk assessment, and supportive oncology. She is currently a Professor in the Department of Clinical Cancer Prevention at the University of Texas MD Anderson, where she has been a faculty member from 2000 to 2018 and 2024 to present.

Administratively, Dr. Row was Chief of Oncology for Summit Health (2018 to 2023) where she was responsible for the development and expansion of the Summit Health multidisciplinary oncology clinical and research program in Northern New Jersey. Under Dr. Row's leadership, the program expanded from one site to three sites and became American College of Surgeons Commission on Cancer accredited. She was Vice President Clinical Operations for the MD Anderson Cancer Network (2012 to 2018) and was responsible for the successful development, implementation, and operations of MD Anderson Cancer Network clinical programs throughout the US and the world.

After graduating with distinction from George Washington University of Medicine in 1994, Dr. Row completed her residency training in Internal Medicine at Baylor College of Medicine. She received a Master of Science in Exercise Science from Arizona State University in 1990 and completed an MBA in 2007 at the McCombs School of Business at the University of Texas. She completed the City of Hope Intensive Course in Genomic Cancer Risk Assessment in 2021. She is a fellow of the American College of Physicians, board certified in Internal Medicine, and licensed to practice medicine in Texas. She is a member of the American Society of Clinical Oncology and the American Society of Sports Medicine.



HOPE S. RUGO, MD, FASCO

Professor of Medicine and Winterhof Family Professor of Breast Oncology Director, Breast Oncology and Clinical Trials Education Medical Dir., Cancer Infusion Services, Division of Hematology/Oncology
UCSF Helen Diller Family Comprehensive Cancer Center

Hope S. Rugo is a Professor of Medicine in the Division of Hematology / Oncology at the University of California, San Francisco (UCSF). She is Director of Breast Oncology and Clinical Trials Education at UCSF's Helen Diller Family Comprehensive Cancer Center. Dr. Rugo is an internationally recognized expert in breast cancer. Her research interests include novel therapies for advanced breast cancer, immune modulation to restore chemotherapy sensitivity, evaluation of circulating tumor DNA as a marker of response and resistance to therapy, neoadjuvant therapy, and safety/supportive care.

She is a principal investigator of multiple clinical trials and has published widely in medical journals. Dr. Rugo also plays an active role in the Alliance for Clinical Trials in Oncology, the Translational Breast Cancer Research Consortium, ASCO, MASCC, and international guideline committees including NCCN. Dr. Rugo is dedicated to education and mentorship, providing guidance to medical students, residents, and fellows at UCSF and beyond.

Panelist Bios



GLEN STETTIN, MD

Chief Innovation Officer
Evernorth

Dr. Glen Stettin is a champion for new solutions to our clients' and patients' biggest healthcare challenges - affordability, poor care and outcomes, poor experiences and the inequity that amplifies these challenges for members of disadvantaged and marginalized communities. For more than 25 years, Dr. Stettin has been leading innovation, clinical and technical development, and advancing analytic approaches for understanding these big challenges and prompting action on behalf of the clients and patients of the health services businesses that have become Evernorth.

As Chief Innovation Officer, Dr. Stettin applies his expertise in diagnostic and treatment strategies, the behavioral sciences and data science to address the most complex and challenging issues in the coverage and delivery of quality health care. Dr. Stettin's team includes the leaders of the Evernorth Research Institute, which focuses on deeply understanding the big healthcare challenges and approaches to solving them, Evernorth's chief patient and physician experience officers, the heads of our advanced data and analytic capabilities and services, and Evernorth Labs, which brings together more than 200 experts, including physicians, nurses, pharmacists, data scientists and software engineers, across sites in three cities, designed for innovation and collaboration, to focus on solving client and patient pain points, through rapid prototyping, in-house development and partnerships with clients and industry innovators.

Dr. Stettin joined the Cigna Corporation in 2018 through the acquisition of Express Scripts, where he had served as senior vice president & chief innovation officer. He came to Express Scripts in 2012 with the acquisition of Medco, where he served as chief medical officer and, for 17 years, in leadership positions in nearly every corporate function with exception of finance, legal and human resources.

Dr. Stettin completed his residency in internal medicine at the University of California, San Francisco, where he also served as medical chief resident and assistant chief of the medical service, Moffitt Hospital, fellow in cardiology and Robert Wood Johnson Clinical Scholar (UCSF/Stanford). He earned his medical and bachelor's degrees through the joint accelerated program of the Medical College of Pennsylvania and Lehigh University



CORNELIA ULRICH, PhD, MS

Chief Scientific Officer and Executive Director, Comprehensive Cancer Center, *Huntsman Cancer Institute*
Jon M. and Karen Huntsman Presidential Professor in Cancer Research, *University of Utah, Salt Lake City, Utah*

Dr. Cornelia Ulrich is the Executive Director of the Comprehensive Cancer Center at Huntsman Cancer Institute (HCI). She is also a Jon M. and Karen Huntsman Presidential Professor in Cancer Research in the Department of Population Health Sciences at the University of Utah. As Chief Scientific Officer and Cancer Center Executive Director, Dr. Ulrich oversees HCI's academic consortium of more than 230 cancer research teams. She is a cancer epidemiologist whose research focuses on lifestyle and biologic factors in cancer prevention and cancer prognosis. Dr. Ulrich leads an interdisciplinary team of scientists on research related to the prevention, epidemiology, prognosis, and survivorship of cancer. She is also Principal Investigator of the HCI Total Cancer Care Protocol in the ORIEN network of cancer centers.

Ulrich's lab has performed landmark research on colorectal cancer prevention and survivorship, including studies on biomarkers, aspirin and connections between obesity and physical activity in cancer prevention and survivorship. She has conducted several clinical trials, is the author of over 420 publications, and has served as principal investigator on more than 23 competitively funded research studies and clinical trials. She is a former Fulbright scholar, an elected member of the Board of the American Association of Cancer Institutes (AACI) and the European Academy of Cancer Sciences, a member of the Executive Leadership in Academic Medicine (ELAM) program, and serves on numerous editorial boards and advisory boards for agencies such as the National Institutes of Health (NIH), AACI, National Academies of Sciences and Medicine (NASEM), International Agency for Research on Cancer (IARC), and the American Association for Cancer Research (AACR).

Ulrich's research interests include: cancer epidemiology and cancer survivorship (esp. colorectal cancer), exercise intervention trials among cancer patients, exercise or energy balance impact biomarkers of cancer risk and outcomes, health behaviors and state-of-the-art biomarkers for cancer etiology, treatment, and survivorship.

For more information, visit:

<http://uofuhealth.utah.edu/huntsman/labs/ulrich/>



SUNIL VERMA, MD

Senior Vice President, Global Head, Oncology Franchise
AstraZeneca

Doctor Sunil Verma serves as the Global Head, Oncology Franchise helping to oversee the global strategy of our Oncology portfolio and our work to transform cancer care in partnership with health systems globally. Prior to joining AstraZeneca, Doctor Verma worked as a Medical Oncologist, specializing in breast cancer and lung cancer care. He has had a prolific impact on Cancer care and has helped to advance the development of a number of pivotal therapies that have shaped cancer care globally. He held positions as Professor and Head of the Department of Oncology at the University of Calgary, along with serving as the Medical Director of the Tom Baker Cancer Centre.

Meyer Consulting is an international health care consulting firm that brings leading experts together in collaborative settings to build better health care solutions.





MEYER CONSULTING

Phone (406) 531-5505

www.meyerconsultinginc.com